Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of “Hold” by Analysts

Arvinas, Inc. (NASDAQ:ARVN) has earned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $15.4167.

ARVN has been the topic of a number of recent research reports. BTIG Research increased their price objective on Arvinas from $16.00 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Stephens reiterated an “overweight” rating and issued a $18.00 target price on shares of Arvinas in a research report on Wednesday, June 3rd. Truist Financial set a $10.00 price target on shares of Arvinas in a research report on Wednesday, March 18th. Weiss Ratings cut Arvinas from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 25th. Finally, Barclays lifted their target price on shares of Arvinas from $18.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th.

Arvinas Stock Performance

ARVN stock opened at $8.39 on Tuesday. The company has a market capitalization of $541.32 million, a price-to-earnings ratio of -2.53 and a beta of 1.74. Arvinas has a fifty-two week low of $6.05 and a fifty-two week high of $14.51. The stock has a fifty day moving average of $8.68 and a 200-day moving average of $10.88.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.95) by $0.05. Arvinas had a negative net margin of 247.54% and a negative return on equity of 44.38%. The company had revenue of $15.60 million for the quarter, compared to analyst estimates of $16.61 million. During the same quarter in the previous year, the firm posted $1.14 earnings per share. The company’s quarterly revenue was down 91.7% compared to the same quarter last year. Equities analysts predict that Arvinas will post -2.82 EPS for the current year.

Insider Activity

In other news, CFO Andrew Saik sold 11,139 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total value of $110,721.66. Following the completion of the sale, the chief financial officer directly owned 193,128 shares of the company’s stock, valued at approximately $1,919,692.32. This trade represents a 5.45% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Noah Berkowitz sold 11,108 shares of Arvinas stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $9.94, for a total transaction of $110,413.52. Following the sale, the insider directly owned 191,395 shares in the company, valued at $1,902,466.30. The trade was a 5.49% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 41,728 shares of company stock valued at $402,649. Company insiders own 7.30% of the company’s stock.

Institutional Trading of Arvinas

Several institutional investors and hedge funds have recently bought and sold shares of ARVN. TCG Crossover Management LLC bought a new stake in Arvinas during the 3rd quarter valued at approximately $13,780,000. Balyasny Asset Management L.P. raised its position in shares of Arvinas by 469.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 1,207,267 shares of the company’s stock worth $10,286,000 after acquiring an additional 995,125 shares in the last quarter. Qube Research & Technologies Ltd lifted its stake in shares of Arvinas by 154.8% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,486,864 shares of the company’s stock valued at $12,668,000 after purchasing an additional 903,337 shares during the period. Millennium Management LLC lifted its stake in shares of Arvinas by 208.4% in the 1st quarter. Millennium Management LLC now owns 1,310,326 shares of the company’s stock valued at $9,198,000 after purchasing an additional 885,483 shares during the period. Finally, Armistice Capital LLC boosted its position in shares of Arvinas by 114.3% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock valued at $10,224,000 after purchasing an additional 640,000 shares in the last quarter. 95.19% of the stock is currently owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.